NTLA News and Press, Intellia Therapeutics Inc.

2026-03-09 16:07:53 ET Investment Overview I have been covering CRISPR Therapeutics AG ( CRSP ), the Zug, Switzerland-based gene therapy developer that leverages the Nobel Prize-winning CRISPR /Cas9 gene editing biotechnology pioneered by Dr. Emmanuelle Charpentier, a sc...

2026-03-09 11:28:03 ET Overview Intellia Therapeutics’ stock ( NTLA ) is flat since my “ Sell ” rating earlier this year. This is a company advancing its in vivo gene therapies: mainly for ATTR and HAE. I’ve expressed caution in the past. Both ATT...

2026-03-09 07:10:16 ET Cathie Wood’s ARK Invest snapped up shares in e-commerce, fintech and next-generation aviation companies while trimming positions in satellite communications, semiconductors and streaming firms in the week through March 6.... Read the full article on Seek...

2026-03-08 17:48:00 ET Cathie Wood, the CEO of the investment management firm Ark Invest, is known for focusing on companies with significant innovative potential. One of her firm's picks, Intellia Therapeutics (NASDAQ: NTLA) , fits the bill. Intellia is a mid-cap biotech compan...

2026-03-05 10:05:27 ET More on iShares Core S&P Small-Cap ETF, Vanguard Small-Cap Index Fund ETF Shares, etc. Read the full article on Seeking Alpha For further details see: Most and least shorted small-to-mid-cap stocks

2026-03-03 09:35:51 ET More on Short interest: Hims & Hers short interest climbs amid legal risk related to weight loss pill... Michael Saylor’s Strategy tops U.S. short list, but high short interest may not signal...

2026-03-03 09:00:27 ET Next-generation cellular therapies and regenerative medicine drive exponential expansion New York, NY – March 3, 2026 – Market News Updates News Commentary – The global anti-aging therapy market is gaining serious momentum as peopl...

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced details about its presentation of four posters at th...

2026-03-02 16:10:43 ET More on Intellia Therapeutics Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 Intellia Therapeutics: Maintaining A Sell Rating As Platform Ri...

2026-03-02 12:15:06 ET Bank of America Securities analyst issues NEUTRAL recommendation for NTLA on March 2, 2026 03:25PM ET. The previous analyst recommendation was Neutral. NTLA was trading at $15.1 at issue of the analyst recommendation. The overall analyst consensus ...